SCHEMBL6879369

SCHEMBL6879369

CC(C)(C)c1ccc(C=Cc2cccc(C=Cc3ccccc3)c2C23CC4CC(C2)CC(c2c(C=Cc5ccccc5)cccc2C=Cc2ccc(C(C)(C)C)cc2)(C4)C3(c2c(C=Cc3ccccc3)cccc2C=Cc2ccc(C(C)(C)C)cc2)c2c(C=Cc3ccccc3)cccc2C=Cc2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
SIGMAR1 Q99720 4/20 0.39
GRIN2D O15399 2/20 0.39
GRIN3B O60391 2/20 0.39
GRIN1 Q05586 2/20 0.39
GRIN2A Q12879 2/20 0.39
GRIN2B Q13224 2/20 0.39
GRIN2C Q14957 2/20 0.39
GRIN3A Q8TCU5 2/20 0.39
TRPV1 Q8NER1 1/20 0.34
CHRNA7 P36544 1/20 0.34
NFE2L2 Q16236 3/20 0.34
POLB P06746 1/20 0.34
HTT P42858 1/20 0.34
BRD4 O60885 2/20 0.33
CREBBP Q92793 2/20 0.33
GABBR2 O75899 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRB2 P47870 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6546384 0.72 CYP1A2 (0.55) NR1H2NR1H3TRPV1NFE2L2POLB
SCHEMBL7535089 0.72 CYP1A2 (0.55) NR1H2NR1H3TRPV1NFE2L2POLB
SCHEMBL28779440 0.72 CYP1A2 (0.55) NR1H2NR1H3TRPV1NFE2L2POLB
SCHEMBL6879354 0.71 SIGMAR1 (0.36) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL6884403 0.71 SIGMAR1 (0.42) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL6884408 0.71 SIGMAR1 (0.42) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL6876798 0.70 NR1H2 (0.49) NR1H2NR1H3TRPV1NFE2L2POLB
SCHEMBL1205645 0.66 CHAT (0.59) NR1H2NR1H3CHRNA7
SCHEMBL1205644 0.66 CHAT (0.59) NR1H2NR1H3CHRNA7
SCHEMBL2748308 0.65 CYP1A2 (0.52) NR1H2NR1H3TRPV1NFE2L2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055278-A1 Soluble tetrahedral compounds for use in electroluminescent devices NATIONAL SCIENCE FOUNDATION 2003-03-20 US claimed
US-6824890-B2 TOPOLOGICAL STRATEGY FOR DESIGNING AMORPHOUS MOLECULAR SOLIDS FOR FORMING THIN FILMS IN OPTOELECTRONIC DEVICES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-11-30 US disclosed
US-20030055278-A1 Soluble tetrahedral compounds for use in electroluminescent devices NATIONAL SCIENCE FOUNDATION 2003-03-20 US disclosed
WO-2001083410-A1 SOLUBLE TETRAHEDRAL COMPOUNDS FOR USE IN ELECTROLUMINESCENT DEVICES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055278-A1 Soluble tetrahedral compounds for use in electroluminescent devices PAX3, EPCAM, PAXBP1 NR1H2 2967/4885NR1H3 2725/4885SIGMAR1 3677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.